Pharvaris N V's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Pharvaris N V's ROI in the fourth quarter of 2025?
Pharvaris N V recorded a cumulative net loss of $-248 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -72.78%.

Within the Healthcare sector 612 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from to 4437.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) II. Quarter
Y / Y Investment Change TTM	2.89 %	9.04 %	33.18 %	90.9 %	78.33 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	352	338	338	338	302
Return On Investment (TTM)	-72.78 %	-25.44 %	-31.74 %	-38.8 %	-42.62 %
PHVS's Overall Ranking	# 4437	#	#	#	# 4518
Seq. Investment Change TTM	3.85 %	-2.9 %	-7.1 %	9.83 %	10.06 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-248	-84	-107	-141	-141

PHVS Company Profile >> Back to PHVS Roi Comparisons >> See Annual PHVS Return On Investment

Return On Investment PHVS's Ranking
Within:	No.
Industry	# 262
Sector	# 613
Overall	# 4437

Return On Investment Statistics
High	Average	Low
-21.07 %	-38.99 %	-56.41 %
(Dec 31 2021)		(Dec 31 2025)

News about Pharvaris N v Return on Investment ROI

Setting a Solid Financial Course: Pharvaris Appoints Accomplished CFO to Propel Growth and Innovation

April 10, 2024

Pharvaris Appoints Seasoned Financial Expert as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 - Pharvaris, a leading biopharmaceutical company specializing in the development of innovative oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, has recently announced the appointment of David Nassif, J.D., as its new Chief Financial Officer. The appointment will be effective from April 15, 2024. Nassif will assume responsibility for refining and implementing Pharvaris corporate financial strategy and activities, which include financial reporting and operations. With over three decades of extensive experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal matters, and capital allocation, Nassif s arrival is expected to greatly enhance Pharvaris financial outlook.
Nassif s arrival at Pharvaris comes at a crucial time for the company, as it moves towards the final stages of developing groundbreaking treatments for HAE. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, potentially leading to life-threatening respiratory difficulties. Pharvaris bradykinin B2 receptor antagonists are designed to inhibit the excessive production of bradykinin, a key mediator of inflammation believed to trigger HAE attacks. By developing an oral form of the antagonist, Pharvaris aims to provide patients with a convenient and effective treatment option that eliminates the need for frequent injections.

Financial Statements
Pharvaris N V's IV. Quarter Investments	$ 352 Millions	PHVS's Balance sheet
Pharvaris N V's IV. Quarter Income	$ -197 Millions	Quarterly PHVS's Income Statement
PHVS's Income by Division		See PHVS's Income by Division

PHVS Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	352	302	441	180	240
Y / Y Investment Growth	16.77 %	-31.62 %	144.52 %	-24.83 %	94.93 %
Net Income in Millions	-199	-145	-109	-80	-51
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-56.41 %	-48.15 %	-24.74 %	-44.58 %	-21.07 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PHVS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PHVS's Competitors
Subscribers only: Roi for Pharvaris N V's Suppliers
Subscribers only: Return On Investment for PHVS's Customers

Other Ratios
PHVS's Roa	PHVS's Inventory Turnover Ratio	PHVS's Growth Rates	PHVS's Dividend Statistics
	PHVS's Profitability Ratios	PHVS's Asset Turnover Ratio	PHVS's Dividend Growth
PHVS's Roe	PHVS's Valuation Ratios	PHVS's Financial Strength Ratios	PHVS's Dividend Payout Ratio

Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector

ROI

Date modified: 2026-07-07T12:34:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.